Plain-English translation of NCT06375486 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called AK112, which works in two ways to fight liver cancer. You would receive AK112 as an infusion every three weeks, combined with chemotherapy that is delivered directly into the blood vessels feeding your liver tumor. The goal is to see whether this combination can shrink tumors and help people with advanced liver cancer live longer.
Advanced liver cancer that cannot be removed by surgery is very difficult to treat, and current options are limited. Researchers believe that combining this new medication—which helps the immune system fight cancer and cuts off blood supply to tumors—with targeted chemotherapy may offer better results than either treatment alone.
You will visit the hospital every three weeks to receive the medication as an infusion. Every six weeks during the first year, you will have imaging scans (like CT or MRI) to see how your tumor is responding. You will continue this treatment for up to 24 months, unless your doctor determines the treatment is no longer helping, you experience unacceptable side effects, or your cancer progresses. After treatment ends, you will have follow-up visits to monitor your health and watch for any return of cancer.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China